AR053582A1 - TETRAHYDRONAFTALINE DERIVATIVES PROCEDURES FOR PREPARATION AND USE AS ANTI-INFLAMMATORY - Google Patents

TETRAHYDRONAFTALINE DERIVATIVES PROCEDURES FOR PREPARATION AND USE AS ANTI-INFLAMMATORY

Info

Publication number
AR053582A1
AR053582A1 ARP060101489A ARP060101489A AR053582A1 AR 053582 A1 AR053582 A1 AR 053582A1 AR P060101489 A ARP060101489 A AR P060101489A AR P060101489 A ARP060101489 A AR P060101489A AR 053582 A1 AR053582 A1 AR 053582A1
Authority
AR
Argentina
Prior art keywords
group
groups
optionally substituted
alkyl
atoms
Prior art date
Application number
ARP060101489A
Other languages
Spanish (es)
Inventor
Anne Mengel
Konrad Krolilkiewicz
Stefan Baurle
Heike Schacke
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of AR053582A1 publication Critical patent/AR053582A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/44—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton bound to carbon atoms of the same ring or condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Procedimientos para su preparacion y con s uso como antiinflamatorios. Reivindicacion 1: Compuestos de formula general 1 caracterizada porque R1 y R2, independientemente uno del otro, son un átomo de hidrogeno, un grupo hidroxilo, un átomo de halogeno, un grupo (C1-10)-alquilo opcionalmente sustituido, un grupo (C1-10)alcoxilo, un grupo (C1-10)-alquiltiol, un grupo (C1-5)-perfluoroalquilo, un grupo ciano, un grupo nitro o un grupo -NR9R9a, o R1 y R2 forman juntos un grupo seleccionado del grupo que consiste en -0-(CH2)n-O-, -O-(CH2)n-CH2-, -O-CH=CH-, -(CH2)n+2-, -NH-(CH2)n+1-, - N(C1-3-alquil)-(CH2)n+1- y -NH-N=CH-, donde n= 1 o 2 y los átomos de oxígeno y/o los átomos de carbono y/o los átomos de nitrogeno terminales están unidos a los átomos de carbono del anillo directamente adyacentes, R11 es un átomo de halogeno, un grupo ciano, un grupo (C1-10)-alquilo opcionalmente sustituido, un grupo (C1-10)-alcoxilo, un grupo (C1-10)-alquiltiol o un grupo (C1-5)- perfluoroalquilo, R12 es un átomo de hidrogeno, un grupo hidroxilo, un átomo de halogeno, un grupo ciano, un grupo hidroxilo, un átomo de halogeno, un grupo ciano, un grupo ( C1-10)-alquilo opcionalmente sustituido o un grupo (C1-10)-alcoxilo, R3 es un grupo (C1-10-alquilo opcionalmente sustituido con entre 1 y 3 grupos hidroxilo, entre 1 y 3 átomos de halogeno y/o entre 1 y 3 grupos (C1-5)-alcoxilo, un grupo (C3-7)-cicloalquilo opcionalmente sustituido, un grupo heterociclilo opcionalmetne sustituido, , un grupo arilo opcionalmente sustituido, un grupo heteroarilo mono o bicíclico que conteine entre 1 y 4 átomos de nitrogeno, y/o 1 o 2 átomos de oxígeno, y/o 10 2 átomos de azufre, y/o 1 o 2 grupos ceto, opcionalmente sustituido con uno o más grupos que, independientemente sustituido con uno o más grupos que, independientemente uno del otro, se seleccionan entre grupos (C1-5)-alquilo, que a a su vez pueden estar opcionalmetne sustituidos con entre 1 y 3 grupos hidroxilo, o entre 1 y 3 grupos -COOR13, grupos (C1-5)-alcoxilo, átomos de halogeno, grupos hidroxilo, grupos -NR9R9a, y grupos exometileno, donde este grupo está unido con el grupo X a través de una posicion arbitraria, y opcionalmente puede estar hidrogenado en una o más posiciones, R4 es un grupo hidroxilo, un grupo -OR10 o un grupo -OR10 o un grupo - O(OR)R10, R6 es un átomo de hidrogeno, un átomo de halogeno, o un grupo (C1-10)-alquilo opcionalmente sustituidio, R7 y R8, independientemente uno del otro, representan un átomo de hidrogeno, un átomo de halogeno, un grupo (C1-10)-alquilo opcionalmetne sustituido, un grupo ciano, juntos representan un grupo (C1-10)-alquilideno, o junto con el átomo de carbono del sistema de tetrahidronaftalina, representan un anillo de (C3-6)-cicloalquilo opcionalmente sustituido; o R6 y R7 forman juntos un carbo o heterociclo condensado de entre cinco y ocho miembros, saturado o insaturado, que está opcionalmente sustituido con 1 o 2 grupos ceto, 1 o 2 grupos (C1-5)-alquilo, 1 o 2 grupos (C1-5)-alcoxilo, y/o entre 1 y 4 átomos de halogeno; o R1 y R8 forman juntos un carbo o heterociclo condensado de entre cinco y ocho miembros, saturado o insaturado, que está opcionalmente sustituido con 1 o 2 grupos ceto, 1 o 2 grupos (C1-5)-alquilo, 1 o 2 grupos (C1-5)-alcoxilo, y/o entre 1 y 4 átomos de halogeno; R9 y R9a, independientemente uno del otro, son un átomos de hidrogeno, (C1-5)-alquilo o -)CO)-(C1-5)-alquilo, R10 representa un grupo (C1-10)- alquilo o un grupo (C1-5)-alquilo, y X representa un enlace o un grupo -C(=O)-, -C(=S)-, -O-, C(=O)-, -O-C(=O)-O-, -O-C)= O)-NH-, -(CH2)p (donde p = 1, 2 o 3 ), un grupo -(CH2)p-NH- ( donde p = 1, 2 o 3) o un grupo -NH-, donde, cuando X contiene una funcion carbonilo o tiocarbonilo, esta funcion está unida al grupo -NH- en na formula general 1 en la forma de un estereoisomero arbitrario o una mezcla de estereoisomeros, o como una sal o un derivado inofensivo desde el punto de vista farmacologico.Procedures for its preparation and with its use as anti-inflammatories. Claim 1: Compounds of general formula 1 characterized in that R1 and R2, independently of one another, are a hydrogen atom, a hydroxyl group, a halogen atom, an optionally substituted (C1-10) -alkyl group, a (C1 -10) alkoxy, a (C1-10) -alkylthiol group, a (C1-5) -perfluoroalkyl group, a cyano group, a nitro group or a -NR9R9a group, or R1 and R2 together form a group selected from the group that consists of -0- (CH2) nO-, -O- (CH2) n-CH2-, -O-CH = CH-, - (CH2) n + 2-, -NH- (CH2) n + 1-, - N (C1-3-alkyl) - (CH2) n + 1- and -NH-N = CH-, where n = 1 or 2 and oxygen atoms and / or carbon atoms and / or atoms of Nitrogen terminals are attached to the directly adjacent ring carbon atoms, R11 is a halogen atom, a cyano group, an optionally substituted (C1-10) -alkyl group, a (C1-10) -alkoxy group, a group ( C1-10) -alkylthiol or a group (C1-5) - perfluoroalkyl, R12 is a hydrogen atom, a hydroxyl group, a halogen atom, a cyano group, a hydroxyl group, a halogen atom, a cyano group, an optionally substituted (C1-10) -alkyl group or a (C1-10) -alkoxy group, R3 is a (C1-10-optionally alkyl group substituted with between 1 and 3 hydroxyl groups, between 1 and 3 halogen atoms and / or between 1 and 3 (C1-5) -alkoxy groups, an optionally substituted (C3-7) -cycloalkyl group, an optionally substituted heterocyclyl group, , an optionally substituted aryl group, a mono or bicyclic heteroaryl group containing between 1 and 4 nitrogen atoms, and / or 1 or 2 oxygen atoms, and / or 10 2 sulfur atoms, and / or 1 or 2 keto groups , optionally substituted with one or more groups that, independently substituted with one or more groups that, independently of each other, are selected from (C1-5) -alkyl groups, which in turn may be optionally substituted with between 1 and 3 groups hydroxyl, or between 1 and 3 -COOR13 groups, (C1-5) -alkoxy groups, halogen atoms, hydroxyl groups, g ruptures -NR9R9a, and exomethylene groups, where this group is linked to group X through an arbitrary position, and optionally can be hydrogenated in one or more positions, R4 is a hydroxyl group, a group -OR10 or a group -OR10 or a group - O (OR) R10, R6 is a hydrogen atom, a halogen atom, or an optionally substituted (C1-10) -alkyl group, R7 and R8, independently of each other, represent a hydrogen atom, a halogen atom, an optionally substituted (C1-10) -alkyl group, a cyano group, together represent a (C1-10) -alkylidene group, or together with the carbon atom of the tetrahydronaphthalene system, represent a ring of ( C3-6) optionally substituted cycloalkyl; or R6 and R7 together form a condensed carbo or heterocycle of between five and eight members, saturated or unsaturated, which is optionally substituted with 1 or 2 keto groups, 1 or 2 (C1-5) -alkyl groups, 1 or 2 groups ( C1-5) -alkoxy, and / or between 1 and 4 halogen atoms; or R1 and R8 together form a condensed carbo or heterocycle of between five and eight members, saturated or unsaturated, which is optionally substituted with 1 or 2 keto groups, 1 or 2 (C1-5) -alkyl groups, 1 or 2 groups ( C1-5) -alkoxy, and / or between 1 and 4 halogen atoms; R9 and R9a, independently of each other, are a hydrogen atoms, (C1-5) -alkyl or -) CO) - (C1-5) -alkyl, R10 represents a (C1-10) -alkyl group or a group (C1-5) -alkyl, and X represents a bond or a group -C (= O) -, -C (= S) -, -O-, C (= O) -, -OC (= O) - O-, -OC) = O) -NH-, - (CH2) p (where p = 1, 2 or 3), a group - (CH2) p-NH- (where p = 1, 2 or 3) or a group -NH-, where, when X contains a carbonyl or thiocarbonyl function, this function is linked to the group -NH- in a general formula 1 in the form of an arbitrary stereoisomer or a mixture of stereoisomers, or as a salt or a harmless derivative from the pharmacological point of view.

ARP060101489A 2005-04-14 2006-04-17 TETRAHYDRONAFTALINE DERIVATIVES PROCEDURES FOR PREPARATION AND USE AS ANTI-INFLAMMATORY AR053582A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005017316A DE102005017316A1 (en) 2005-04-14 2005-04-14 Tetrahydronaphthalene derivatives, process for their preparation and their use as anti-inflammatory agents

Publications (1)

Publication Number Publication Date
AR053582A1 true AR053582A1 (en) 2007-05-09

Family

ID=36889239

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101489A AR053582A1 (en) 2005-04-14 2006-04-17 TETRAHYDRONAFTALINE DERIVATIVES PROCEDURES FOR PREPARATION AND USE AS ANTI-INFLAMMATORY

Country Status (8)

Country Link
AR (1) AR053582A1 (en)
DE (1) DE102005017316A1 (en)
DO (1) DOP2006000089A (en)
GT (1) GT200600152A (en)
PE (1) PE20061360A1 (en)
TW (1) TW200716565A (en)
UY (1) UY29482A1 (en)
WO (1) WO2006108713A2 (en)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63220242A (en) * 1987-03-10 1988-09-13 Fuji Photo Film Co Ltd Photoresist composition
EP0291327A3 (en) * 1987-05-15 1989-01-25 Schering Corporation Aryl-substituted naphthalene, benzoxepine, benzazepine and benzocycloheptene derivatives
EP0370056A1 (en) * 1987-07-16 1990-05-30 Byk Gulden Lomberg Chemische Fabrik Gmbh New diazols
US5059609A (en) * 1987-10-19 1991-10-22 Pfizer Inc. Substituted tetralins, chromans and related compounds in the treatment of asthma, arthritis and related diseases
JPH0641038A (en) * 1992-07-17 1994-02-15 Mitsubishi Kasei Corp Carboxylic acid derivative
US5489584A (en) * 1994-12-29 1996-02-06 Allergan, Inc. Acetylenes disubstituted with a 5-amino or substituted 5-amino substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
AU8591898A (en) * 1997-07-22 1999-02-16 Eli Lilly And Company Pharmaceutical compounds
GB9716244D0 (en) * 1997-07-31 1997-10-08 Electrophoretics International Pharmaceutical compounds
US6333337B1 (en) * 1998-01-27 2001-12-25 Icagen, Inc. Potassium channel inhibitors
US6013830A (en) * 1998-03-30 2000-01-11 Sepracor Inc. Asymmetric grignard synthesis with cyclic 1,2 aminoalcohols
AU5682299A (en) * 1998-08-21 2000-03-14 Scripps Research Institute, The Catalytic asymmetric aminohydroxylation with amino-substituted heterocycles
JP2000256255A (en) * 1999-03-10 2000-09-19 Kuraray Co Ltd Optical resolution of (±)-trans-permethrinic acid
SE9903930D0 (en) * 1999-10-29 1999-10-29 Astra Pharma Inc Novel compounds and a novel process for their preparation
ES2193839B1 (en) * 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. NEW DERIVATIVES OF 6-PHENYLDIHYDROPIRROLPIRIMIDINDIONA.
CN1556788A (en) * 2001-09-21 2004-12-22 Muscarinic agonists
AR036608A1 (en) * 2001-09-24 2004-09-22 Bayer Corp IMIDAZOL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF OBESITY
AU2002343557A1 (en) * 2001-11-21 2003-06-10 Pharmacia And Upjohn Company Substituted aryl 1,4-pyrazine derivatives
US6875866B2 (en) * 2002-02-21 2005-04-05 Schering Corporation Process for synthesis of D1 receptor antagonists
AU2003258538A1 (en) * 2002-08-26 2004-03-19 Merck Patent Gmbh Cyclopenta(b)naphthalene derivatives
DE112004001265D2 (en) * 2003-08-22 2006-07-06 Merck Patent Gmbh Cyclopenta (a) naphthalene
CN1239441C (en) * 2003-09-12 2006-02-01 中国科学院上海有机化学研究所 Method for processing asymmetric hydroxylamination and dihydroxylation reaction by use of supported bi-cinchoni alkaloid ligand

Also Published As

Publication number Publication date
DOP2006000089A (en) 2006-11-15
GT200600152A (en) 2007-03-19
UY29482A1 (en) 2006-10-31
WO2006108713A3 (en) 2006-12-14
PE20061360A1 (en) 2007-01-26
WO2006108713A2 (en) 2006-10-19
TW200716565A (en) 2007-05-01
DE102005017316A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
AR061564A1 (en) DERIVATIVES OF ISOINDOLS, PHARMACEUTICAL COMPOSITIONS AND USES
AR061369A1 (en) PIRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM
AR093924A2 (en) HEPATITIS C SERINA PROTEASAS MACROCICLIC INHIBITORS
AR056949A1 (en) DERIVATIVES OF TETRAHYDRONAFTALINE, PROCEDURES FOR THEIR PREPARATION AND ITS USE AS AN INFLAMMATION INHIBITOR
AR055016A1 (en) TRICYCLE AMINOALCOHOLES, PROCEDURES FOR THE PREPARATION AND USE FOR THE PREPARATION OF MEDICINES
AR061371A1 (en) AMINO - IMIDAZOLONAS AND ITS USE AS A MEDICINAL PRODUCT FOR ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES.
AR078535A1 (en) PIRROLO DERIVATIVES [2,3-B] PYRIDINE LIGANDOS OF STROGEN RECEPTORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THE SAME IN THE TREATMENT OF THE OSTEOPOROSIS AND DISEASES OF THE CENTRAL NERVOUS SYSTEM, AMONG OTHER
AR061370A1 (en) IMIDAZOPIRIMIDINE DERIVATIVES
AR084553A1 (en) HIDEROCICLIC INHIBITING IMIDAZOLIC DERIVATIVES OF b-SECRETASE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THE SAME TO TREAT NEURODEGENERATIVE DISEASES, IN PARTICULAR ALZHEIMER
CO5680443A2 (en) DERIVATIVES OF BENCIMIDAZOL, COMPOSITIONS THAT CONTAIN THEM, PREPARATION OF THE SAME AND USES OF THE SAME
AR059896A1 (en) STEREOISOMERIC DERIVATIVES OF TETRAHYDRONAFTALENE, METHOD OF PREPARATION, MEDICATIONS CONTAINING THEM, AND USE AS ANTI-INFLAMMATORY AGENTS.
UY27095A1 (en) BENZIMIDAZOL AND PIRIDILIMIDAZOL DERIVATIVES AS LIGANDOS FOR GABA
CO6220949A2 (en) PIRAZOLIC DERIVATIVES AS INHIBITORS OF THE 11 BETA -HSD1
AR057984A1 (en) IMIDAZOL DERIVATIVES INHIBITORS OF PROTEIN beta AMILOID
AR066290A1 (en) HETEROCICLICAL DERIVATIVES, PROCESSES FOR THEIR PRODUCTION, DRUGS THAT UNDERSTAND THESE COMPOUNDS AND THEIR USE
AR061651A1 (en) PIRIDINE ANALOGS II
AR043434A1 (en) PIPERIZACINE DERIVATIVES ACILATED AS AGELISTS OF THE RECEIVER OF MELANOCORTINA-4. PHARMACEUTICAL COMPOSITIONS AND USES
PA8564201A1 (en) N-SUBSTITUTED SPIROPIPERIDINE COMPOUNDS AS LIGANDS FOR ORL-1 RECEIVER
AR070207A1 (en) BICYCLE DERIVATIVES OF CARBOXAMIDAS AZA- BICICLICAS ITS PREPARATION AND ITS THERAPEUTIC APPLICATION
AR092955A1 (en) ANTAGONISTS OF OREXINE RECEIVERS WHICH ARE DERIVED FROM [ORTO BI- (IET-) ARIL] - [2- (META BI- (IET-) ARIL) -PIRROLIDIN-1-IL] -METANONA
DOP2009000232A (en) METANOISOINDOLES AND DIONAS OF THESE AS ANTI-PSYCHOTIC AGENTS.
AR069490A1 (en) GLUCOCORTICOID RECEPTORS AGONISTS
AR045856A1 (en) TROPANO DERIVATIVES REPLACED WITH IMIDAZOPIRIDINS, PREPARATION PROCEDURE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES,
AR066478A1 (en) REPLACED HETEROCICLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS
AR071068A1 (en) SUBSTITUTED SPIROCYCLIC CYCLHEXAN DERIVATIVES

Legal Events

Date Code Title Description
FA Abandonment or withdrawal